Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion

Aghdam, K.A. and Reznicek, L. and Sanjari, M.S. and Framme, C. and Bajor, A. and Klingenstein, A. and Kernt, M. and Seidensticker, F. (2016) Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion. International Journal of Ophthalmology, 9 (6). pp. 858-862.

Preview

Text Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion.pdf Download (440kB) | Preview

Abstract

� AIM: To evaluate the association between the size of peripheral retinal non-perfusion and the number of intravitreal ranibizumab injections in patients with treatment-naive branch retinal vein occlusion (BRVO) and macular edema. � METHODS: A total of 53 patients with treatment-naive BRVO and macular edema were included. Each patient underwent a full ophthalmologic examination including optical coherence tomography (OCT) imaging and ultra wide-field fluorescein angiography (UWFA). Monthly intravitreal ranibizumab injections were applied according to the recommendations of the German Ophthalmological Society. Two independent, masked graders quantified the areas of peripheral retinal non-perfusion. � RESULTS: Intravitreal injections improved best-corrected visual acuity (BCVA) significantly from 22.23±16.33 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters to 36.23±15.19 letters (P<0.001), and mean central subfield thickness significantly reduced from 387±115 µm to 321±115 µm (P=0.01). Mean number of intravitreal ranibizumab injections was 3.61±1.56. The size of retinal non-perfusion correlated significantly with the number of intravitreal ranibizumab injections (R=0.724, P<0.001). � CONCLUSION: Peripheral retinal non-perfusion in patients with BRVO associates significantly with intravitreal ranibizumab injections in patients with BRVO and macular edema. © 2016, International Journal of Ophthalmology (c/o Editorial Office). All rights reserved.

Actions (login required)

View Item